Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM, Sia JE, Rahman OU, Ahmad M, Shahid N, Gardezi SA, Joseph KV, Behary Paray N, Zulfiqar E

Cardiology in review19 Feb 2026

PMID41711462DOI10.1097/crd.0000000000001209PepBankPUB-41711462

Publisher page PubMedAsk about this study

Jump to 27 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study27

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone27

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin polyagonists (tirzepatide, retatrutide, mazdutide) reduced body weight more than placebo.
In plain wordsIn adults with obesity, dual and triple incretin drugs together lowered body weight more than placebo in pooled trials.
Peptide
Mazdutide
Outcome
DecreaseBody weight (pooled mean difference)
Study
n = 3,236
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference body weight
−11.47 NR
pooled polyagonists
Source sentences
Summary
Incretin polyagonists significantly reduced body weight compared to placebo (MD -11.47; 95% CI: -14.00 to -8.95).
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146201
02HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
Pooled incretin polyagonists reduced waist circumference in obese adults.
In plain wordsIn adults with obesity, dual and triple incretin drugs together reduced waist size in pooled trials.
Peptide
Mazdutide
Outcome
DecreaseWaist circumference (pooled mean difference)
Study
n = 3,236
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference waist circumference
−9.4 NR
pooled polyagonists
Source sentences
Summary
Significant reductions were also observed in waist circumference (MD -9.40; 95% CI: -11.91 to -6.89)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146202
03HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
Pooled incretin polyagonists reduced glycated hemoglobin in obese adults.
In plain wordsIn adults with obesity, dual and triple incretin drugs together lowered glycated hemoglobin in pooled trials.
Peptide
Mazdutide
Outcome
DecreaseGlycated hemoglobin (pooled mean difference)
Study
n = 3,236
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference HbA1c
−0.96 NR
pooled polyagonists
Source sentences
Summary
glycated hemoglobin (MD -0.96; 95% CI: -1.16 to -0.75)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146203
04HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
Pooled incretin polyagonists reduced fasting plasma glucose in obese adults.
In plain wordsIn adults with obesity, dual and triple incretin drugs together lowered fasting blood glucose in pooled trials.
Peptide
Mazdutide
Outcome
DecreaseFasting plasma glucose (pooled mean difference)
Study
n = 3,236
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference fasting plasma glucose
−26.89 mg/dL
pooled polyagonists
Source sentences
Summary
fasting plasma glucose (MD -26.89 mg/dL; 95% CI: -33.48 to -20.30).
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146204
05HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
Pooled dual and triple agonists were associated with a higher risk of any adverse event.
In plain wordsIn pooled trials in adults with obesity, dual and triple incretin drugs were linked to more adverse events overall.
Peptide
Mazdutide
Outcome
IncreaseAny adverse events (pooled risk ratio)
Study
n = 3,236
Outcome group
Adverse events · Whole body
Measurements
Risk ratio any AE
1.13 ratio
pooled polyagonists
Source sentences
Summary
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146205
06HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
Pooled dual and triple agonists were associated with a higher risk of gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation).
In plain wordsIn pooled trials in adults with obesity, dual and triple incretin drugs were linked to more stomach and bowel side effects.
Peptide
Mazdutide
Outcome
IncreaseGastrointestinal adverse events (nausea, vomiting, diarrhea, constipation)
Study
n = 3,236
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation)
3 context sentences(design, population, supporting numbers)
Summary · context
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation), AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30), and hypoglycemic episodes (RR 3.…
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146206
07HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
Pooled dual and triple agonists were associated with a higher risk of adverse events leading to withdrawal.
In plain wordsIn pooled trials in adults with obesity, dual and triple incretin drugs were linked to more people stopping because of side effects.
Peptide
Mazdutide
Outcome
IncreaseAdverse events leading to withdrawal (pooled risk ratio)
Study
n = 3,236
Outcome group
Adverse events · Whole body
Measurements
Risk ratio AE withdrawal
1.96 ratio
pooled polyagonists
Source sentences
Summary
AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146207
08HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
Pooled dual and triple agonists were associated with a higher risk of hypoglycemic episodes.
In plain wordsIn pooled trials in adults with obesity, dual and triple incretin drugs were linked to more low blood sugar episodes.
Peptide
Mazdutide
Outcome
IncreaseHypoglycemic episodes (pooled risk ratio)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio hypoglycemia
3.08 ratio
pooled polyagonists
Source sentences
Summary
hypoglycemic episodes (RR 3.08; 95% CI: 1.61-5.89)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146208
09HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
Pooled dual and triple agonists showed no significant difference in serious adverse events.
In plain wordsIn pooled trials in adults with obesity, dual and triple incretin drugs showed no clear difference in serious adverse events.
Peptide
Mazdutide
Outcome
No significant changeSerious adverse events (pooled risk ratio)
Study
n = 3,236
Outcome group
Adverse events · Whole body
Measurements
Risk ratio serious AE
0.87 ratio
pooled polyagonists
Source sentences
Summary
No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14).
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
Summary · context
A total of 10 randomized controlled trials, including 3236 participants, were analyzed.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4171146209
10HumanNot a test of Retatrutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists (tirzepatide, retatrutide, mazdutide) reduced body weight versus placebo.
In plain wordsIn obese adults, a pool of three incretin drugs reduced body weight more than placebo did.
Peptide
Retatrutide
Outcome
DecreaseBody weight (pooled)
Study
n = 3,236
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Incretin polyagonists significantly reduced body weight compared to placebo (MD -11.47; 95% CI: -14.00 to -8.95).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146210
11HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists (tirzepatide, retatrutide, mazdutide) reduced body weight versus placebo.
In plain wordsIn obese adults, a pool of three incretin drugs reduced body weight more than placebo did.
Peptide
Tirzepatide
Outcome
DecreaseBody weight (pooled)
Study
n = 3,236
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Incretin polyagonists significantly reduced body weight compared to placebo (MD -11.47; 95% CI: -14.00 to -8.95).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146211
12HumanNot a test of Retatrutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced waist circumference.
In plain wordsIn obese adults, a pool of three incretin drugs reduced waist size.
Peptide
Retatrutide
Outcome
DecreaseWaist circumference (pooled)
Study
n = 3,236
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Significant reductions were also observed in waist circumference (MD -9.40; 95% CI: -11.91 to -6.89)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146212
13HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced waist circumference.
In plain wordsIn obese adults, a pool of three incretin drugs reduced waist size.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference (pooled)
Study
n = 3,236
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Significant reductions were also observed in waist circumference (MD -9.40; 95% CI: -11.91 to -6.89)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146213
14HumanNot a test of Retatrutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced glycated hemoglobin.
In plain wordsIn obese adults, a pool of three incretin drugs lowered glycated hemoglobin, a long-term blood sugar marker.
Peptide
Retatrutide
Outcome
DecreaseGlycated hemoglobin (pooled)
Study
n = 3,236
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
glycated hemoglobin (MD -0.96; 95% CI: -1.16 to -0.75)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146214
15HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced glycated hemoglobin.
In plain wordsIn obese adults, a pool of three incretin drugs lowered glycated hemoglobin, a long-term blood sugar marker.
Peptide
Tirzepatide
Outcome
DecreaseGlycated hemoglobin (pooled)
Study
n = 3,236
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
glycated hemoglobin (MD -0.96; 95% CI: -1.16 to -0.75)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146215
16HumanNot a test of Retatrutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced fasting plasma glucose.
In plain wordsIn obese adults, a pool of three incretin drugs lowered fasting blood sugar.
Peptide
Retatrutide
Outcome
DecreaseFasting plasma glucose (pooled)
Study
n = 3,236
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference in fasting plasma glucose
−26.89 mg/dL
pooled incretin polyagonists
Source sentences
Summary
and fasting plasma glucose (MD -26.89 mg/dL; 95% CI: -33.48 to -20.30).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146216
17HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In obese adults, pooled incretin dual and triple agonists significantly reduced fasting plasma glucose.
In plain wordsIn obese adults, a pool of three incretin drugs lowered fasting blood sugar.
Peptide
Tirzepatide
Outcome
DecreaseFasting plasma glucose (pooled)
Study
n = 3,236
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference in fasting plasma glucose
−26.89 mg/dL
pooled incretin polyagonists
Source sentences
Summary
and fasting plasma glucose (MD -26.89 mg/dL; 95% CI: -33.48 to -20.30).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146217
18HumanNot a test of Retatrutide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of any adverse events.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more adverse events overall.
Peptide
Retatrutide
Outcome
IncreaseAny adverse events (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
1.13 ratio
any adverse events
Source sentences
Summary
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146218
19HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of any adverse events.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more adverse events overall.
Peptide
Tirzepatide
Outcome
IncreaseAny adverse events (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
1.13 ratio
any adverse events
Source sentences
Summary
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146219
20HumanNot a test of Retatrutide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation).
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more stomach and bowel side effects.
Peptide
Retatrutide
Outcome
IncreaseGastrointestinal adverse events (pooled)
Study
n = 3,236
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146220
21HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation).
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more stomach and bowel side effects.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events (pooled)
Study
n = 3,236
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146221
22HumanNot a test of Retatrutide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of adverse events leading to withdrawal.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more people stopping because of side effects.
Peptide
Retatrutide
Outcome
IncreaseAdverse events leading to withdrawal (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
1.96 ratio
adverse events leading to withdrawal
Source sentences
Summary
AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146222
23HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of adverse events leading to withdrawal.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more people stopping because of side effects.
Peptide
Tirzepatide
Outcome
IncreaseAdverse events leading to withdrawal (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
1.96 ratio
adverse events leading to withdrawal
Source sentences
Summary
AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146223
24HumanNot a test of Retatrutide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of hypoglycemic episodes.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more episodes of low blood sugar.
Peptide
Retatrutide
Outcome
IncreaseHypoglycemic episodes (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
3.08 ratio
hypoglycemic episodes
Source sentences
Summary
hypoglycemic episodes (RR 3.08; 95% CI: 1.61-5.89)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146224
25HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists were associated with a higher risk of hypoglycemic episodes.
In plain wordsIn obese adults, a pool of three incretin drugs was linked to more episodes of low blood sugar.
Peptide
Tirzepatide
Outcome
IncreaseHypoglycemic episodes (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
3.08 ratio
hypoglycemic episodes
Source sentences
Summary
hypoglycemic episodes (RR 3.08; 95% CI: 1.61-5.89)
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146225
26HumanNot a test of Retatrutide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists showed no significant difference in serious adverse events.
In plain wordsIn obese adults, a pool of three incretin drugs showed no significant difference in serious side effects.
Peptide
Retatrutide
Outcome
No significant changeSerious adverse events (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
0.87 ratio
serious adverse events
Source sentences
Summary
No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.
Report a problemFND-4171146226
27HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In obese adults, pooled dual and triple agonists showed no significant difference in serious adverse events.
In plain wordsIn obese adults, a pool of three incretin drugs showed no significant difference in serious side effects.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events (pooled)
Study
n = 3,236
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
0.87 ratio
serious adverse events
Source sentences
Summary
No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4171146227

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:04 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.